Development and characterization of novel erythropoiesis stimulating protein (NESP)

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 3, 2001, Pages 3-13

  Egrie, J C ^a   Browne, J K ^a  

^a AMGEN INC   (United States)

Author keywords

Biological activity; Carbohydrate; Darbepoetin alfa; Erythropoietin; Pharmacokinetics; Review

Indexed keywords

CARBOHYDRATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE;

EID: 0034949634     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_3.3     Document Type: Article

References (43)

1. Erythropoietin
2. Biology of erythropoietin
3. Expression cloning of the murine erythropoietin receptor
4. The erythropoietin receptor: Biogenesis, dimerization, and intracellular signal transduction
5. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis
6. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
7. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
8. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
9. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications
10. Use of recombinant human erythropoietin outside the setting of uremia
11. The safety of treatment with recombinant human erythropoietin in clinical use: A review of controlled studies
12. The role of carbohydrate on the biological activity of erythropoietin
13. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO)
14. Purification of human erythropoietin
15. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells
16. Structural characterization of human erythropoitein
17. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin
18. Erythropoietin: Gene cloning, protein structure, and biological properties
19. Characterization and biological effects of recombinant human erythropoietin
20. NMR structure of human erythropoietin and a comparison with its receptor bound conformation
21. Efficiency of signalling through cytokine receptors depends critically on receptor orientation
22. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA
23. Site-specific glycosylation of human recombinant erythropoietin: Analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry
24. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells
25. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins
26. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody
27. Glycosylation of recombinant protein therapeutics: Control and functional implications
28. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion and biological function
29. The effect of carbohydrate on the structure and stability of erythropoietin
30. Role of glycosylation on the secretion and biological activity of erythropoietin
31. Inactivation of erythropoietin by neuraminidase and mild substitution reactions
32. Studies on the role of sialic acid in the physical and biological properties of erythropoietin
33. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action
34. Survival of recombinant erythropoietin in the circulation: The role of carbohydrates
35. The in vivo metabolism of recombinant human erythropoietin in the rat
36. The role of carbohydrate in erythropoietin action
37. Role of sugar chains in the expression of the biological activity of human erythropoietin
38. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide
39. The molecular biology of erythropoietin
40. Erythropoietin structure-function relationships
41. Rational design of novel erythropoiesis stimulating protein (ARANESP™): A super-sialated molecule with increased biological activity
42. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia
43. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients